Background: An optimal management of maternal hyperthyroidism is important for positive pregnancy outcome, and to this end, the Endocrine Society published their guidelines in 2007. This survey aimed to investigate to what extent the clinical practice relating to the management of hyperthyroidism during pregnancy in Europe is uniform and consistent with the guidelines. Materials and Methods: We e-mailed an online questionnaire survey based on clinical case scenarios to 605 members of the European Thyroid Association. We analysed 190 responses from 28 European countries. Results: For a woman with newly diagnosed Graves’ disease (GD) and wishing pregnancy, 78% of the responders would initiate antithyroid drugs (ATDs), while 22% would recommend definitive treatment with radioiodine or surgery. In case of a relapsed GD before pregnancy, 80% preferred definitive treatment. For a woman with newly diagnosed GD during pregnancy, 53% would treat with propylthiouracil, 12% with methimazole, and 34% with propylthiouracil initially and switch to methimazole after the first trimester. Responders used several combinations of tests to monitor the dose of ATDs, and the thyroid test results they targeted were inconsistent. For a lactating woman with GD, 68% would give ATDs without stopping lactation. Conclusions: Variation in the clinical practices surrounding the management of hyperthyroid pregnant women in Europe still exists.

1.
Krassas GE, Poppe K, Glinoer D: Thyroid function and human reproductive health. Endocr Rev 2010;31:702–755.
2.
Lockwood CM, Grenache DG, Gronowski AM: Serum human chorionic gonadotropin concentrations greater than 400,000 IU/l are invariably associated with suppressed serum thyrotropin concentrations. Thyroid 2009;19:863–868.
3.
Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG: Subclinical hyperthyroidism and pregnancy outcomes. Obstet Gynecol 2006;107:337–341.
4.
Glinoer D, Spencer AC: Serum TSH determinations in pregnancy: how, when and why? Nat Rev Endocrinol 2010;6:526–529.
5.
Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S: Fetal loss associated with excess of thyroid hormone exposure. JAMA 2004;292:691–695.
6.
Chan GW, Mandel SJ: Therapy insight: management of Graves’ disease during pregnancy. Nat Clin Pract Endocrinol Metab 2007;3:470–478.
7.
Bowman P, Osborne NJ, Sturley R, Vaidya B: Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. QJM 2011, E-pub ahead of print.
8.
Cooper DS, Rivkees SA: Putting propylthiouracil in perspective. J Clin Endocrinol Metab 2009;94:1881–1882.
9.
Abalovich M, Amino N, Barbour LA, Cobin RH, De Groot LJ, Glinoer D, Mandel SJ, Stagnaro-Green A: Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2007;92:S1–S47.
10.
Vaidya B, Hubalewska-Dydejczyk A, Laurberg P, Negro R, Vermiglio F, Poppe K: Treatment and screening of hypothyroidism in pregnancy: results of a European survey. Eur J Endocrinol 2012;166:49–54.
11.
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W: Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum. Thyroid 2011;21:1081–1125.
12.
Barbero P, Valdez R, Rodríguez H, Tiscornia C, Mansilla E, Allons A, Coll S, Liascovich R: Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study. Am J Med Genet A 2008;15:2390–2395.
13.
Bournaud C, Orgiazzi J: Antithyroid agents and embryopathies. Ann Endocrinol (Paris) 2003;64:366–369.
14.
Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C: Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. Thyroid 2011;21:335–346.
15.
Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM: Free T4 immunoassays are flawed during pregnancy. Am J Obstet Gynecol 2009;200:260.e1–e6.
16.
Anckaert E, Poppe K, Van Uytfanghe K, Schiettecatte J, Foulon W, Thienpont LM: FT4 immunoassays may display a pattern during pregnancy similar to the equilibrium dialysis ID-LC/tandem MS candidate reference measurement procedure in spite of susceptibility towards binding protein alterations. Clin Chim Acta 2010;411:1348–1353.
17.
Hamburger JI: Diagnosis and management of Graves’ disease in pregnancy. Thyroid 1992;2:219–224.
18.
Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J: Management of Graves’ hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. Eur J Endocrinol 2009;160:1–8.
19.
Laurberg P, Nygaard B, Glinoer D, Grussendorf M, Orgiazzi J: Guidelines for TSH-receptor antibody measurements in pregnancy. Eur J Endocrinol 1998;139:584–586.
20.
Glinoer D, De Nayer P, Bourdoux, Lemone M, Robyn C, van Steirteghem A, Kinthaert J, Lejeune B: Regulation of maternal thyroid function during pregnancy. J Clin Endocrinol Metab 1990;71:276–287.
21.
Redmond GP: Propranolol and fetal growth retardation. Semin Perinatol 1982;6:142–147.
22.
Azizi F, Bahrainian M, Khamseh ME, Khoshniatl M: Intellectual development and thyroid function in children who were breast-fed by thyrotoxic mothers taking methimazole. J Pediatr Endocrinol Metab 2003;16:1239–1243.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.